Helus Pharma (DE:R7E)
FRANKFURT:R7E
Total Valuation
Helus Pharma has a market cap or net worth of €1.19M. The enterprise value is €0.00.
Market Cap€1.19M
Enterprise Value€0.00
Share Statistics
Helus Pharma has 50,035,793 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding50,035,793
Owned by Insiders1.29%
Owned by Institutions38.22%
Financial Efficiency
Helus Pharma’s return on equity (ROE) is -0.48 and return on invested capital (ROIC) is -60.35%.
Return on Equity (ROE)-0.48
Return on Assets (ROA)-0.44
Return on Invested Capital (ROIC)-60.35%
Return on Capital Employed (ROCE)-0.60
Revenue Per Employee0.00
Profits Per Employee-2.26M
Employee Count50
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Helus Pharma is ―. Helus Pharma’s PEG ratio is 0.16.
PE Ratio―
PS Ratio0.00
PB Ratio7.14
Price to Fair Value0.72
Price to FCF-16.39
Price to Operating Cash Flow-1.53
PEG Ratio0.16
Income Statement
In the last 12 months, Helus Pharma had revenue of 0.00 and earned -113.14M in profits. Earnings per share was -5.59.
Revenue0.00
Gross Profit-472.27K
Operating Income-143.15M
Pretax Income-113.14M
Net Income-113.14M
EBITDA-142.67M
Earnings Per Share (EPS)-5.59
Cash Flow
In the last 12 months, operating cash flow was -122.82M and capital expenditures -2.24M, giving a free cash flow of -125.06M billion.
Operating Cash Flow-122.82M
Free Cash Flow-125.06M
Free Cash Flow per Share-2.50
Dividends & Yields
Helus Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.55
52-Week Price Change-52.00%
50-Day Moving Average4.17
200-Day Moving Average5.12
Relative Strength Index (RSI)43.99
Average Volume (3m)470.00
Important Dates
Helus Pharma upcoming earnings date is Jul 1, 2026, Before Open (Confirmed).
Last Earnings DateFeb 13, 2026
Next Earnings DateJul 1, 2026
Ex-Dividend Date―
Financial Position
Helus Pharma as a current ratio of 7.75, with Debt / Equity ratio of 0.00%
Current Ratio7.75
Quick Ratio7.75
Debt to Market Cap0.00
Net Debt to EBITDA0.95
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Helus Pharma has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Helus Pharma EV to EBITDA ratio is -0.26, with an EV/FCF ratio of -0.36.
EV to Sales0.00
EV to EBITDA-0.26
EV to Free Cash Flow-0.36
EV to Operating Cash Flow-0.36
Balance Sheet
Helus Pharma has €194.97M in cash and marketable securities with €40.19M in debt, giving a net cash position of €194.97M billion.
Cash & Marketable Securities€194.97M
Total Debt€40.19M
Net Cash€194.97M
Net Cash Per Share€3.90
Tangible Book Value Per Share€7.16
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Helus Pharma is €44.69, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€44.69
Price Target Upside902.06% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast-13.92%